Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1996
|
| gptkbp:ATCCode |
P02CA03
|
| gptkbp:contraindication |
pregnancy
known hypersensitivity to albendazole |
| gptkbp:drugClass |
anthelmintic
|
| gptkbp:eliminationHalfLife |
8.5 hours
|
| gptkbp:excretion |
urine
bile |
| gptkbp:form |
gptkb:tablet
oral suspension |
| gptkbp:genericName |
gptkb:albendazole
|
| https://www.w3.org/2000/01/rdf-schema#label |
Albenza
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
inhibits microtubule synthesis in parasites
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
adults
children |
| gptkbp:prescriptionRequired |
yes
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting abdominal pain dizziness headache elevated liver enzymes |
| gptkbp:treatment |
gptkb:neurocysticercosis
cystic hydatid disease |
| gptkbp:usedFor |
treatment of parasitic infections
|
| gptkbp:bfsParent |
gptkb:albendazole
|
| gptkbp:bfsLayer |
6
|